首页 > 最新文献

Addiction最新文献

英文 中文
Commentary on Keller-Hamilton et al. : Oral nicotine pouches provide a less controversial route for tobacco harm reduction than electronic cigarettes 对 Keller-Hamilton 等人的评论:与电子香烟相比,口服尼古丁袋是一种争议较少的减少烟草危害的途径。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-23 DOI: 10.1111/add.16437
Gideon St.Helen
<p>Keller-Hamilton and colleagues examined the effect of nicotine concentration on nicotine intake and appeal of oral nicotine pouches among smokers [<span>1</span>]. Oral nicotine pouches, which contain nicotine but not tobacco plant material, entered the United States market in 2016 [<span>2</span>] and the European market, such as the United Kingdom, in 2019 [<span>3</span>]. Approximately a decade before that, electronic cigarettes (e-cigarettes) made their first entry into global markets [<span>4</span>] and became a source of controversy among public health practitioners, researchers and clinicians. E-cigarettes have undergone several iterations in their design, from those that resembled the shape and size of traditional cigarettes to the current variations of disposable and rechargeable pod devices. The liquids used in e-cigarettes have also evolved, from those that contained primarily freebase nicotine in a solution of vegetable glycerin (VG) and propylene glycol (PG) to those now formulated with the more appealing and potentially more addictive nicotine salts [<span>5</span>]. In addition, a number of countries or local jurisdictions have implemented policies restricting access to flavors, such as bans on all or a subset of flavors, or restricting sale of flavors to adult-only stores [<span>6</span>].</p><p>Although there is considerable variation, e-cigarettes can deliver as much nicotine as traditional cigarettes and in a way in which the blood nicotine profile closely matches that of cigarettes [<span>7</span>]. As such e-cigarettes have been lauded and shown to support smoking cessation among adults in clinical trials [<span>8</span>], although evidence at the population level is mixed [<span>9</span>].</p><p>Despite the potential benefits to adult smokers, there is justifiable concern regarding e-cigarette use among teens. Since the introduction of the more appealing nicotine salt-containing and flavored disposable and rechargeable pod devices in global markets between 2015 and 2018, millions of teens have used e-cigarettes. For example, in 2019, 27.5% (4.1 million) of high school students and 10.5% (1.2 million) of middle school students in the United States had used e-cigarettes in the past 30 days [<span>10</span>]. In that same year, 12.4% of 16-year-olds in Europe reported using e-cigarettes in the past 30 days, ranging from 5.5% in Serbia to 41.4% in Monaco [<span>11</span>]. More recently, in 2023, 10.0% of US high school students and 4.6% of US middle school students had used e-cigarettes in the past 30 days [<span>12</span>], a noticeable decline from 2019. While the prevalence of e-cigarette use among US teens has decreased somewhat, e-cigarettes remain the most widely used tobacco product among US teens [<span>12</span>]. The high appeal and adoption of e-cigarettes relative to traditional cigarettes among teens (and the potential to lead to smoking) complicates messaging of e-cigarettes as a form of tobacco harm reductio
简而言之,鉴于尼古丁袋能够向使用者提供大量尼古丁,但相对于传统香烟和潜在的电子烟,其吸引力和毒性较低,因此尼古丁袋可以作为一种减少烟草危害的形式。与电子烟相比,烟草控制界、研究人员和监管机构可以更广泛地接受采用尼古丁袋来减少烟草危害。
{"title":"Commentary on Keller-Hamilton et al. : Oral nicotine pouches provide a less controversial route for tobacco harm reduction than electronic cigarettes","authors":"Gideon St.Helen","doi":"10.1111/add.16437","DOIUrl":"10.1111/add.16437","url":null,"abstract":"&lt;p&gt;Keller-Hamilton and colleagues examined the effect of nicotine concentration on nicotine intake and appeal of oral nicotine pouches among smokers [&lt;span&gt;1&lt;/span&gt;]. Oral nicotine pouches, which contain nicotine but not tobacco plant material, entered the United States market in 2016 [&lt;span&gt;2&lt;/span&gt;] and the European market, such as the United Kingdom, in 2019 [&lt;span&gt;3&lt;/span&gt;]. Approximately a decade before that, electronic cigarettes (e-cigarettes) made their first entry into global markets [&lt;span&gt;4&lt;/span&gt;] and became a source of controversy among public health practitioners, researchers and clinicians. E-cigarettes have undergone several iterations in their design, from those that resembled the shape and size of traditional cigarettes to the current variations of disposable and rechargeable pod devices. The liquids used in e-cigarettes have also evolved, from those that contained primarily freebase nicotine in a solution of vegetable glycerin (VG) and propylene glycol (PG) to those now formulated with the more appealing and potentially more addictive nicotine salts [&lt;span&gt;5&lt;/span&gt;]. In addition, a number of countries or local jurisdictions have implemented policies restricting access to flavors, such as bans on all or a subset of flavors, or restricting sale of flavors to adult-only stores [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Although there is considerable variation, e-cigarettes can deliver as much nicotine as traditional cigarettes and in a way in which the blood nicotine profile closely matches that of cigarettes [&lt;span&gt;7&lt;/span&gt;]. As such e-cigarettes have been lauded and shown to support smoking cessation among adults in clinical trials [&lt;span&gt;8&lt;/span&gt;], although evidence at the population level is mixed [&lt;span&gt;9&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Despite the potential benefits to adult smokers, there is justifiable concern regarding e-cigarette use among teens. Since the introduction of the more appealing nicotine salt-containing and flavored disposable and rechargeable pod devices in global markets between 2015 and 2018, millions of teens have used e-cigarettes. For example, in 2019, 27.5% (4.1 million) of high school students and 10.5% (1.2 million) of middle school students in the United States had used e-cigarettes in the past 30 days [&lt;span&gt;10&lt;/span&gt;]. In that same year, 12.4% of 16-year-olds in Europe reported using e-cigarettes in the past 30 days, ranging from 5.5% in Serbia to 41.4% in Monaco [&lt;span&gt;11&lt;/span&gt;]. More recently, in 2023, 10.0% of US high school students and 4.6% of US middle school students had used e-cigarettes in the past 30 days [&lt;span&gt;12&lt;/span&gt;], a noticeable decline from 2019. While the prevalence of e-cigarette use among US teens has decreased somewhat, e-cigarettes remain the most widely used tobacco product among US teens [&lt;span&gt;12&lt;/span&gt;]. The high appeal and adoption of e-cigarettes relative to traditional cigarettes among teens (and the potential to lead to smoking) complicates messaging of e-cigarettes as a form of tobacco harm reductio","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 3","pages":"476-477"},"PeriodicalIF":6.0,"publicationDate":"2024-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16437","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139540918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distributions of alcohol use and alcohol-caused death and disability in Canada: Defining alcohol harm density functions and new perspectives on the prevention paradox 加拿大酒精使用及酒精导致死亡和残疾的分布情况:定义酒精危害密度函数和预防悖论的新视角。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-18 DOI: 10.1111/add.16414
Adam Sherk, Samuel Churchill, Samantha Cukier, Sierra C. Grant, Kevin Shield, Tim Stockwell

Aims

The aims of this study were to examine the distribution of alcohol use and to define ‘harm density functions’ representing distributions of alcohol-caused health harm in Canada, by sex, towards better understanding which groups of drinkers experience the highest aggregate harms.

Design

This was an epidemiological modeling study using survey and administrative data on alcohol exposure, death and disability and risk relationships from epidemiological meta-analyses.

Setting

This work took place in Canada, 2019.

Participants

Canadians aged 15 years or older participated.

Measurements

Measures included modeled life-time mean daily alcohol use in grams of pure alcohol (ethanol) per day, alcohol-caused deaths and alcohol-caused disability-adjusted life-years.

Findings

As a life-time average, more than half of Canadians aged 15+ (62.8% females, 46.9% males) use fewer than 10 g of pure alcohol per day (g/day). By volume, the top 10% of the population consume 45.9% of the total ethanol among males and 47.1% of the total ethanol among females. The remaining 90% of the population experience a slim majority of alcohol-caused deaths (males 55.3%, females 46.9%). Alcohol harm density functions compose the size of the using population and the risk experienced at each volume level to show that the population-level harm experienced is highest for males at 25 g/day and females at 13 g/day.

Conclusions

Almost 50% of alcohol use in Canada is concentrated among the highest 10% of drinkers, but more than half of the alcohol-caused deaths in Canada in 2019 were experienced by the bottom 90% of the population by average volume, providing evidence for the prevention paradox. New alcohol harm density functions provide insight into the aggregate health harm experienced across the mean alcohol use spectrum and may therefore be used to help determine where alcohol policies should be targeted for highest efficacy.

目的:本研究的目的是研究酒精使用的分布情况,并按性别定义代表加拿大酒精造成的健康危害分布情况的 "危害密度函数",以便更好地了解哪些饮酒群体受到的总体危害最大:这是一项流行病学建模研究,使用了有关酒精暴露、死亡和残疾的调查和管理数据,以及流行病学荟萃分析中的风险关系:这项工作于 2019 年在加拿大进行:年龄在 15 岁或以上的加拿大人参加:测量指标包括以每日纯酒精(乙醇)克数为单位的模型化终生平均每日饮酒量、酒精导致的死亡人数和酒精导致的残疾调整寿命年数:在 15 岁以上的加拿大人中,超过半数(62.8% 的女性和 46.9% 的男性)一生平均每天纯酒精摄入量少于 10 克。按消费量计算,前 10%的人口所消费的乙醇占男性乙醇总量的 45.9%,占女性乙醇总量的 47.1%。其余 90% 的人口因酒精导致的死亡占绝大多数(男性 55.3%,女性 46.9%)。酒精危害密度函数由饮酒人口的规模和每个量级的风险组成,表明男性每天饮酒 25 克,女性每天饮酒 13 克,对人口造成的危害最大:加拿大近50%的酒精使用集中在饮酒量最高的10%人群中,但2019年加拿大因酒精导致的死亡中,超过一半是由平均饮酒量最低的90%人群造成的,这为预防悖论提供了证据。新的酒精危害密度函数提供了对平均酒精使用范围内总体健康危害的深入了解,因此可用于帮助确定酒精政策应针对哪些方面以取得最大成效。
{"title":"Distributions of alcohol use and alcohol-caused death and disability in Canada: Defining alcohol harm density functions and new perspectives on the prevention paradox","authors":"Adam Sherk,&nbsp;Samuel Churchill,&nbsp;Samantha Cukier,&nbsp;Sierra C. Grant,&nbsp;Kevin Shield,&nbsp;Tim Stockwell","doi":"10.1111/add.16414","DOIUrl":"10.1111/add.16414","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aims of this study were to examine the distribution of alcohol use and to define ‘harm density functions’ representing distributions of alcohol-caused health harm in Canada, by sex, towards better understanding which groups of drinkers experience the highest aggregate harms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>This was an epidemiological modeling study using survey and administrative data on alcohol exposure, death and disability and risk relationships from epidemiological meta-analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting</h3>\u0000 \u0000 <p>This work took place in Canada, 2019.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Participants</h3>\u0000 \u0000 <p>Canadians aged 15 years or older participated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>Measures included modeled life-time mean daily alcohol use in grams of pure alcohol (ethanol) per day, alcohol-caused deaths and alcohol-caused disability-adjusted life-years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>As a life-time average, more than half of Canadians aged 15+ (62.8% females, 46.9% males) use fewer than 10 g of pure alcohol per day (g/day). By volume, the top 10% of the population consume 45.9% of the total ethanol among males and 47.1% of the total ethanol among females. The remaining 90% of the population experience a slim majority of alcohol-caused deaths (males 55.3%, females 46.9%). Alcohol harm density functions compose the size of the using population and the risk experienced at each volume level to show that the population-level harm experienced is highest for males at 25 g/day and females at 13 g/day.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Almost 50% of alcohol use in Canada is concentrated among the highest 10% of drinkers, but more than half of the alcohol-caused deaths in Canada in 2019 were experienced by the bottom 90% of the population by average volume, providing evidence for the prevention paradox. New alcohol harm density functions provide insight into the aggregate health harm experienced across the mean alcohol use spectrum and may therefore be used to help determine where alcohol policies should be targeted for highest efficacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 4","pages":"696-705"},"PeriodicalIF":6.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139490424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial 电子烟和尼古丁贴片作为孕期戒烟辅助工具的安全性:电子烟和贴片妊娠试验(PREP)随机对照试验的二次分析。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-17 DOI: 10.1111/add.16422
Francesca Pesola, Katie Myers Smith, Anna Phillips-Waller, Dunja Przulj, Christopher Griffiths, Robert Walton, Hayden McRobbie, Tim Coleman, Sarah Lewis, Rachel Whitemore, Miranda Clark, Michael Ussher, Lesley Sinclair, Emily Seager, Sue Cooper, Linda Bauld, Felix Naughton, Peter Sasieni, Isaac Manyonda, Peter Hajek
<div> <section> <h3> Aims</h3> <p>The aim of this study was to examine the safety of e-cigarettes (EC) and nicotine patches (NRT) when used to help pregnant smokers quit.</p> </section> <section> <h3> Design</h3> <p>A recent trial of EC versus NRT reported safety outcomes in the randomized arms. We conducted a further analysis based on product use.</p> </section> <section> <h3> Setting</h3> <p>Twenty-three hospitals in England and a stop-smoking service in Scotland took part.</p> </section> <section> <h3> Participants</h3> <p>The participants comprised 1140 pregnant smokers.</p> </section> <section> <h3> Interventions</h3> <p>We compared women using and not using EC and NRT regularly during pregnancy.</p> </section> <section> <h3> Measurements</h3> <p>Measurements included nicotine intake compared with baseline, birth weight, other pregnancy outcomes, adverse events, maternal respiratory symptoms and relapse in early abstainers.</p> </section> <section> <h3> Findings</h3> <p>Use of EC was more common than use of NRT (47.3% vs 21.6%, <i>P</i> < 0.001). Women who stopped smoking (abstainers) and used EC at the end-of-pregnancy (EOP) reduced their salivary cotinine by 45% [49.3 ng/ml, 95% confidence interval (CI) = −79.8 to −10]. Only one abstainer used NRT at EOP. In dual users, cotinine increased by 19% (24 ng/ml, 95% CI = 3.5–68). In women reporting a reduction of at least 50% in cigarette consumption, cotinine levels increased by 10% in those using nicotine products and by 9% in those who did not. Birth weights in dual users and exclusive smokers were the same (3.1 kg). Birth weight in abstainers using either nicotine product was higher than in smokers [3.3 kg, standard deviation (SD) = 0.7] versus 3.1 kg, SD = 0.6; difference = 0.15 kg, 95% CI = 0.05–0.25) and not different from abstainers not using nicotine products (3.1 kg, SD = 0.8). Abstainers and smokers using nicotine products had no worse pregnancy outcomes or more adverse events than abstainers and smokers not using them. EC users reported more improvements than non-users in cough [adjusted relative risk (aRR) = 0.59, 95% CI = 0.37–0.93] and phlegm (aRR = 0.53, 95% CI = 0.31–0.92), controlling for smoking status. EC or NRT use had no association with relapse.</p> </secti
目的:本研究旨在探讨电子烟(EC)和尼古丁贴片(NRT)用于帮助怀孕吸烟者戒烟的安全性:最近一项关于电子烟与尼古丁贴片的试验报告了随机试验组的安全性结果。我们根据产品使用情况进行了进一步分析:英格兰的 23 家医院和苏格兰的一家戒烟服务机构参与了这项研究:干预措施:干预措施:我们对怀孕期间定期使用和未使用EC和NRT的妇女进行了比较:测量指标包括与基线相比的尼古丁摄入量、出生体重、其他妊娠结局、不良事件、孕产妇呼吸道症状以及早期戒烟者的复吸情况:使用电子烟比使用 NRT 更为普遍(47.3% 对 21.6%,P 结论):吸烟孕妇定期使用电子烟或尼古丁贴片似乎与任何不良后果无关。
{"title":"Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial","authors":"Francesca Pesola,&nbsp;Katie Myers Smith,&nbsp;Anna Phillips-Waller,&nbsp;Dunja Przulj,&nbsp;Christopher Griffiths,&nbsp;Robert Walton,&nbsp;Hayden McRobbie,&nbsp;Tim Coleman,&nbsp;Sarah Lewis,&nbsp;Rachel Whitemore,&nbsp;Miranda Clark,&nbsp;Michael Ussher,&nbsp;Lesley Sinclair,&nbsp;Emily Seager,&nbsp;Sue Cooper,&nbsp;Linda Bauld,&nbsp;Felix Naughton,&nbsp;Peter Sasieni,&nbsp;Isaac Manyonda,&nbsp;Peter Hajek","doi":"10.1111/add.16422","DOIUrl":"10.1111/add.16422","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The aim of this study was to examine the safety of e-cigarettes (EC) and nicotine patches (NRT) when used to help pregnant smokers quit.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A recent trial of EC versus NRT reported safety outcomes in the randomized arms. We conducted a further analysis based on product use.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Twenty-three hospitals in England and a stop-smoking service in Scotland took part.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The participants comprised 1140 pregnant smokers.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Interventions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We compared women using and not using EC and NRT regularly during pregnancy.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Measurements&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Measurements included nicotine intake compared with baseline, birth weight, other pregnancy outcomes, adverse events, maternal respiratory symptoms and relapse in early abstainers.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Findings&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Use of EC was more common than use of NRT (47.3% vs 21.6%, &lt;i&gt;P&lt;/i&gt; &lt; 0.001). Women who stopped smoking (abstainers) and used EC at the end-of-pregnancy (EOP) reduced their salivary cotinine by 45% [49.3 ng/ml, 95% confidence interval (CI) = −79.8 to −10]. Only one abstainer used NRT at EOP. In dual users, cotinine increased by 19% (24 ng/ml, 95% CI = 3.5–68). In women reporting a reduction of at least 50% in cigarette consumption, cotinine levels increased by 10% in those using nicotine products and by 9% in those who did not. Birth weights in dual users and exclusive smokers were the same (3.1 kg). Birth weight in abstainers using either nicotine product was higher than in smokers [3.3 kg, standard deviation (SD) = 0.7] versus 3.1 kg, SD = 0.6; difference = 0.15 kg, 95% CI = 0.05–0.25) and not different from abstainers not using nicotine products (3.1 kg, SD = 0.8). Abstainers and smokers using nicotine products had no worse pregnancy outcomes or more adverse events than abstainers and smokers not using them. EC users reported more improvements than non-users in cough [adjusted relative risk (aRR) = 0.59, 95% CI = 0.37–0.93] and phlegm (aRR = 0.53, 95% CI = 0.31–0.92), controlling for smoking status. EC or NRT use had no association with relapse.&lt;/p&gt;\u0000 &lt;/secti","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"875-884"},"PeriodicalIF":6.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Community Reinforcement and Family Training versus counselling for parents of treatment-refusing young adults with hazardous substance use: A randomized controlled trial 社区强化和家庭培训与针对拒绝接受治疗并使用有害物质的青少年父母的辅导:随机对照试验。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-16 DOI: 10.1111/add.16429
Ola Siljeholm, Kerstin Edvardsson, Malin Bergström, Anders Hammarberg
<div> <section> <h3> Background and aims</h3> <p>Despite the high prevalence and negative effects of hazardous substance use, few young adults enter treatment. Community Reinforcement and Family Training (CRAFT), a support programme for concerned significant others of people with substance use disorders, has proved efficacious in promoting treatment entry. The aim of the current trial was to compare the efficacy of CRAFT with an active control for parents of young adults (aged 18–24 years) with hazardous substance use.</p> </section> <section> <h3> Design</h3> <p>This was a randomized controlled superiority trial comparing CRAFT (<i>n</i> = 58) with an active control group receiving manualized counselling (<i>n</i> = 55), with outcome assessments at 6, 12 and 24 weeks (primary end-point). A sequential design with a stopping rule was added post recruitment commencement.</p> </section> <section> <h3> Setting</h3> <p>The study took place in two outpatient clinics for young adults in Stockholm, Sweden, and subsequently via video-conference due to COVID-19.</p> </section> <section> <h3> Participants</h3> <p>Between October 2018 and May 2021, 113 participants (92% female) who were parents of young adults (87% male) were recruited. Recruitment was discontinued when 70% of the planned sample had been recruited, following an interim analysis of the primary outcome showing no difference between conditions.</p> </section> <section> <h3> Intervention and comparator</h3> <p>Participants were randomized (ratio 1 : 1) to eight manual-based individual CRAFT sessions or five individual manual-based counselling sessions + one voluntary psychoeducative group session, delivered over maximum 14 weeks.</p> </section> <section> <h3> Measurements</h3> <p>The primary outcome measure was the rate of young adult entry in substance use treatment during the trial period (24 weeks).</p> </section> <section> <h3> Findings</h3> <p>At the 24 weeks follow-up, 19 (33%) of CRAFT participants and 17 (31%) of counselling participants had reported young adult treatment entry, with no difference between conditions (odds ratio CRAFT versus counselling 0.84, 95% confidence interval = 0.35; 1.99, <i>P</i> = 0.700). Both conditions reported clinically relevant reductions in young adult subst
背景和目的:尽管使用有害物质的发病率很高,而且会产生负面影响,但接受治疗的年轻人却很少。社区强化和家庭培训(CRAFT)是一项针对药物使用障碍患者重要亲属的支持计划,在促进患者接受治疗方面具有显著效果。本次试验的目的是比较 "社区强化和家庭培训 "与积极对照组对有药物使用危险的年轻人(18-24 岁)的父母的疗效:这是一项随机对照优越性试验,将 CRAFT(58 人)与接受人工辅导的积极对照组(55 人)进行比较,分别在 6、12 和 24 周(主要终点)进行结果评估。招募开始后增加了一个带有停止规则的顺序设计:研究在瑞典斯德哥尔摩的两家年轻成人门诊诊所进行,随后因COVID-19而通过视频会议进行:2018年10月至2021年5月期间,共招募了113名参与者(92%为女性),他们都是年轻人的父母(87%为男性)。在对主要结果进行中期分析后发现,不同条件下的结果无差异,因此在招募到计划样本的 70% 后停止招募:受试者被随机分配(比例为 1:1)接受 8 次以人工方式进行的个人 CRAFT 课程或 5 次以人工方式进行的个人咨询课程 + 1 次自愿心理教育小组课程,最长时间为 14 周:主要结果是在试验期间(24 周)青少年接受药物使用治疗的比率:在 24 周的随访中,19 名(33%)CRAFT 参与者和 17 名(31%)心理咨询参与者报告了青少年接受治疗的情况,两种情况之间没有差异(CRAFT 与心理咨询的几率比为 0.84,95% 置信区间 = 0.35;1.99,P = 0.700)。两种情况都报告了临床相关的青少年药物使用减少情况,但参与者的抑郁、焦虑或压力水平没有变化:这项试验表明,在青壮年戒毒治疗方面,社区强化和家庭培训(CRAFT)这一针对药物滥用障碍患者重要亲属的支持项目,比人工咨询更有效,但没有统计学意义。
{"title":"Community Reinforcement and Family Training versus counselling for parents of treatment-refusing young adults with hazardous substance use: A randomized controlled trial","authors":"Ola Siljeholm,&nbsp;Kerstin Edvardsson,&nbsp;Malin Bergström,&nbsp;Anders Hammarberg","doi":"10.1111/add.16429","DOIUrl":"10.1111/add.16429","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Despite the high prevalence and negative effects of hazardous substance use, few young adults enter treatment. Community Reinforcement and Family Training (CRAFT), a support programme for concerned significant others of people with substance use disorders, has proved efficacious in promoting treatment entry. The aim of the current trial was to compare the efficacy of CRAFT with an active control for parents of young adults (aged 18–24 years) with hazardous substance use.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This was a randomized controlled superiority trial comparing CRAFT (&lt;i&gt;n&lt;/i&gt; = 58) with an active control group receiving manualized counselling (&lt;i&gt;n&lt;/i&gt; = 55), with outcome assessments at 6, 12 and 24 weeks (primary end-point). A sequential design with a stopping rule was added post recruitment commencement.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The study took place in two outpatient clinics for young adults in Stockholm, Sweden, and subsequently via video-conference due to COVID-19.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Between October 2018 and May 2021, 113 participants (92% female) who were parents of young adults (87% male) were recruited. Recruitment was discontinued when 70% of the planned sample had been recruited, following an interim analysis of the primary outcome showing no difference between conditions.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Intervention and comparator&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Participants were randomized (ratio 1 : 1) to eight manual-based individual CRAFT sessions or five individual manual-based counselling sessions + one voluntary psychoeducative group session, delivered over maximum 14 weeks.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Measurements&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The primary outcome measure was the rate of young adult entry in substance use treatment during the trial period (24 weeks).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Findings&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;At the 24 weeks follow-up, 19 (33%) of CRAFT participants and 17 (31%) of counselling participants had reported young adult treatment entry, with no difference between conditions (odds ratio CRAFT versus counselling 0.84, 95% confidence interval = 0.35; 1.99, &lt;i&gt;P&lt;/i&gt; = 0.700). Both conditions reported clinically relevant reductions in young adult subst","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"915-927"},"PeriodicalIF":6.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139471803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on Domzaridou et al.: Recognising the complexities of co-prescriptions and lifestyle factors in opioid agonist treatment 对 Domzaridou 等人的评论:认识阿片类激动剂治疗中合并处方和生活方式因素的复杂性。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-14 DOI: 10.1111/add.16433
Adam Bakker, Alexander Smith, Michael Liebrenz
<p>We read with great interest the study by Domzaridou <i>et al</i>. [<span>1</span>], which examined the risk of non-fatal overdose (NFO) in patients with opioid use disorder who were prescribed opioid agonist treatment (OAT) alongside benzodiazepines, gabapentinoids, antipsychotics, antidepressants and Z-drugs. While applauding their valuable work, we note that differences in risky behaviour and lifestyles between the analysed subpopulations were not addressed.</p><p>For example, their finding that benzodiazepine co-prescribed patients have an increased weighted relative NFO risk of 1.3 (compared with other OAT-patients) seems unsurprising based on wider evidence of risk factors in OAT. It is well-recognised that people with opioid dependency who also misuse benzodiazepines are more difficult to engage in treatment and have increased risk profiles [<span>2</span>]. They are more likely to have injected recently, used borrowed needles, consumed cocaine and practised unsafe sex [<span>3</span>]. They also have more psychiatric morbidity, higher prevalence of alcohol use disorder [<span>4</span>] and more frequent contact with law enforcement [<span>5</span>].</p><p>Benzodiazepine dependence is associated with increased suicide risks, premature death and adverse childhood experiences [<span>6, 7</span>]. Notably, the drug related death-rate triples among individuals with opioid dependency if using illicit benzodiazepines [<span>8</span>] and all-cause mortality is increased too [<span>9</span>]. These cited studies all refer to illicit rather than prescribed benzodiazepines, suggesting that harm reduction programmes should not overlook benzodiazepine problems. Although illicit benzodiazepine consumption often involves chaotic use of very high doses [<span>10</span>], instalment-dispensed prescribed benzodiazepine seems to reduce risky behaviours [<span>11-13</span>].</p><p>Interestingly, the subsequent stratified analysis of the NFO risk by Domzaridou <i>et al</i>. [<span>1</span>] showed very little difference for the periods when benzodiazepine were not co-prescribed in this high-risk group, as judged by the largely overlapping confidence intervals for the periods with and without benzodiazepines (Figure 1). Regrettably, in the abstract, the stated NFO risk for co-prescribing benzodiazepines during OAT is 1.45, based on the figure from the sub-analysis, without mentioning that this did not differ significantly when benzodiazepines were not co-prescribed. This gives an exaggerated impression of the NFO risk for prescribing benzodiazepines.</p><p>That said, an intriguing result from Domzaridou <i>et al</i>. [<span>1</span>] is the increased NFO-risk for patients treated with buprenorphine in comparison with methadone when benzodiazepines or gabapentinoids were co-prescribed. This might seem counter intuitive [<span>14</span>], but one conceivable hypothesis for this could be that the more chaotic lifestyles associated with patients accessing these
我们怀着极大的兴趣阅读了 Domzaridou 等人[1]的研究报告,该报告研究了阿片类药物使用障碍患者非致命过量(NFO)的风险,这些患者在接受阿片类药物激动剂治疗(OAT)的同时还接受苯二氮卓、加巴喷丁类药物、抗精神病药物、抗抑郁药物和 Z 类药物的治疗。我们对他们所做的宝贵工作表示赞赏,但同时也注意到,所分析的亚人群之间在危险行为和生活方式上的差异并没有得到解决。例如,他们发现,与其他 OAT 患者相比,同时服用苯二氮卓类药物的患者的加权相对 NFO 风险增加了 1.3,这一结果似乎并不出人意料,因为有更广泛的证据表明 OAT 患者存在风险因素。众所周知,滥用苯并二氮杂卓的阿片类药物依赖者更难接受治疗,风险也更高[2]。他们最近更有可能注射过阿片、使用过借用针头、吸食过可卡因和进行过不安全性行为[3]。苯二氮卓类药物依赖与自杀风险增加、过早死亡和不良童年经历有关[6, 7]。值得注意的是,如果使用非法苯二氮卓类药物,阿片类药物依赖者的药物相关死亡率会增加三倍[8],全因死亡率也会增加[9]。这些引用的研究都涉及非法而非处方苯并二氮杂卓,这表明减少危害方案不应忽视苯并二氮杂卓问题。虽然非法服用苯二氮卓往往涉及大剂量的混乱使用[10],但分期发放的处方苯二氮卓似乎可以减少危险行为[11-13]。有趣的是,Domzaridou 等人随后对 NFO 风险进行了分层分析[1],结果表明,在没有联合处方苯二氮卓的情况下,这一高风险群体的风险差异很小,这一点可以从使用和不使用苯二氮卓期间基本重叠的置信区间判断出来(图 1)。令人遗憾的是,在摘要中,根据子分析的数据,在 OAT 期间联合处方苯二氮卓类药物的 NFO 风险为 1.45,而没有提及在不联合处方苯二氮卓类药物时,该风险并无显著差异。尽管如此,Domzaridou 等人[1]得出的一个耐人寻味的结果是,与美沙酮相比,联合处方苯二氮卓或加巴喷丁类药物时,接受丁丙诺啡治疗的患者的 NFO 风险增加。这似乎有悖于直觉[14],但一个可以想象的假设是,鉴于丁丙诺啡的治疗保持率较低,美沙酮比丁丙诺啡更能稳定接受这些治疗的患者较为混乱的生活方式[15]。最终,在减低伤害计划中,我们需要考虑如何最好地促进健康生活方式的改变,同时也要认识到药物之间的药理相互作用:构思;写作-原稿。亚历山大-史密斯写作-审稿。迈克尔-利布伦茨A.B.和 A.S.无须声明。M.L.曾多次代表瑞士联邦公共卫生局参与欧洲委员会--毒品和成瘾问题国际合作小组(蓬皮杜小组)的工作。作者没有其他需要声明的利益冲突。任何观点仅代表作者本人。
{"title":"Comment on Domzaridou et al.: Recognising the complexities of co-prescriptions and lifestyle factors in opioid agonist treatment","authors":"Adam Bakker,&nbsp;Alexander Smith,&nbsp;Michael Liebrenz","doi":"10.1111/add.16433","DOIUrl":"10.1111/add.16433","url":null,"abstract":"&lt;p&gt;We read with great interest the study by Domzaridou &lt;i&gt;et al&lt;/i&gt;. [&lt;span&gt;1&lt;/span&gt;], which examined the risk of non-fatal overdose (NFO) in patients with opioid use disorder who were prescribed opioid agonist treatment (OAT) alongside benzodiazepines, gabapentinoids, antipsychotics, antidepressants and Z-drugs. While applauding their valuable work, we note that differences in risky behaviour and lifestyles between the analysed subpopulations were not addressed.&lt;/p&gt;&lt;p&gt;For example, their finding that benzodiazepine co-prescribed patients have an increased weighted relative NFO risk of 1.3 (compared with other OAT-patients) seems unsurprising based on wider evidence of risk factors in OAT. It is well-recognised that people with opioid dependency who also misuse benzodiazepines are more difficult to engage in treatment and have increased risk profiles [&lt;span&gt;2&lt;/span&gt;]. They are more likely to have injected recently, used borrowed needles, consumed cocaine and practised unsafe sex [&lt;span&gt;3&lt;/span&gt;]. They also have more psychiatric morbidity, higher prevalence of alcohol use disorder [&lt;span&gt;4&lt;/span&gt;] and more frequent contact with law enforcement [&lt;span&gt;5&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Benzodiazepine dependence is associated with increased suicide risks, premature death and adverse childhood experiences [&lt;span&gt;6, 7&lt;/span&gt;]. Notably, the drug related death-rate triples among individuals with opioid dependency if using illicit benzodiazepines [&lt;span&gt;8&lt;/span&gt;] and all-cause mortality is increased too [&lt;span&gt;9&lt;/span&gt;]. These cited studies all refer to illicit rather than prescribed benzodiazepines, suggesting that harm reduction programmes should not overlook benzodiazepine problems. Although illicit benzodiazepine consumption often involves chaotic use of very high doses [&lt;span&gt;10&lt;/span&gt;], instalment-dispensed prescribed benzodiazepine seems to reduce risky behaviours [&lt;span&gt;11-13&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Interestingly, the subsequent stratified analysis of the NFO risk by Domzaridou &lt;i&gt;et al&lt;/i&gt;. [&lt;span&gt;1&lt;/span&gt;] showed very little difference for the periods when benzodiazepine were not co-prescribed in this high-risk group, as judged by the largely overlapping confidence intervals for the periods with and without benzodiazepines (Figure 1). Regrettably, in the abstract, the stated NFO risk for co-prescribing benzodiazepines during OAT is 1.45, based on the figure from the sub-analysis, without mentioning that this did not differ significantly when benzodiazepines were not co-prescribed. This gives an exaggerated impression of the NFO risk for prescribing benzodiazepines.&lt;/p&gt;&lt;p&gt;That said, an intriguing result from Domzaridou &lt;i&gt;et al&lt;/i&gt;. [&lt;span&gt;1&lt;/span&gt;] is the increased NFO-risk for patients treated with buprenorphine in comparison with methadone when benzodiazepines or gabapentinoids were co-prescribed. This might seem counter intuitive [&lt;span&gt;14&lt;/span&gt;], but one conceivable hypothesis for this could be that the more chaotic lifestyles associated with patients accessing these","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"965-966"},"PeriodicalIF":6.0,"publicationDate":"2024-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16433","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139465630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022 2016 年至 2022 年美国加利福尼亚州与致幻剂有关的急诊就诊和住院趋势。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-11 DOI: 10.1111/add.16432
Nicolas Garel, Steven Tate, Kristin Nash, Anna Lembke

Background and aims

Hallucinogens encompass a diverse range of compounds of increasing scientific and public interest. Risks associated with hallucinogen use are under-researched and poorly understood. We aimed to compare the trends in hallucinogen-associated health-care use with alcohol- and cannabis-associated health-care use.

Design, setting and cases

We conducted an ecological study with publicly available data on International Classification of Diseases, 10th Revision (ICD-10) diagnosis codes associated with emergency department (ED) visits and hospitalizations from the California Department of Healthcare Access and Information (HCAI). HCAI includes primary and secondary ICD-10 codes reported with ED or hospital discharge from every non-federal health-care facility licensed in California, United States, from 2016 to 2022.

Measurements

ICD-10 codes were classified as hallucinogen-, cannabis- or alcohol-associated if they were from the corresponding category in the ICD-10 block ‘mental and behavioral disorders due to psychoactive substance use’.

Findings

Observed hallucinogen-associated ED visits increased by 54% between 2016 and 2022, from 2260 visits to 3476 visits, compared with a 20% decrease in alcohol-associated ED visits and a 15% increase in cannabis-associated ED visits. The observed hallucinogen-associated hospitalizations increased by 55% during the same period, from 2556 to 3965 hospitalizations, compared with a 1% increase in alcohol-associated hospitalizations and a 1% increase in cannabis-associated hospitalizations. This rise in hallucinogenic ED visits was significantly different from the trend in cannabis-associated (P < 0.001) and alcohol-associated (P = 0.005) ED visits. The hallucinogen-associated hospitalizations trend also significantly differed when compared with cannabis- (P < 0.001) and alcohol-associated (P < 0.001) hospitalizations.

Conclusions

Hallucinogen-associated emergency department visits and hospitalizations in California, USA, showed a large relative but small absolute increase between 2016 and 2022.

背景和目的:致幻剂包括多种多样的化合物,越来越受到科学界和公众的关注。人们对使用致幻剂的相关风险研究不足,了解甚少。我们的目的是比较与使用致幻剂有关的医疗保健与使用酒精和大麻有关的医疗保健的趋势:我们利用加利福尼亚州医疗保健访问和信息部(HCAI)公开提供的与急诊科(ED)就诊和住院相关的国际疾病分类第十版(ICD-10)诊断代码数据开展了一项生态研究。HCAI 包括 2016 年至 2022 年期间美国加利福尼亚州所有获得许可的非联邦医疗机构报告的与急诊室就诊或出院相关的主要和次要 ICD-10 代码:如果ICD-10代码属于ICD-10 "使用精神活性物质导致的精神和行为障碍 "中的相应类别,则被归类为与致幻剂、大麻或酒精相关:2016年至2022年间,观察到的致幻剂相关急诊就诊人次增加了54%,从2260人次增至3476人次,而酒精相关急诊就诊人次减少了20%,大麻相关急诊就诊人次增加了15%。同期观察到的致幻剂相关住院人数增加了 55%,从 2556 人次增至 3965 人次,而酒精相关住院人数增加了 1%,大麻相关住院人数增加了 1%。致幻剂引发的急诊就诊人次的增加与大麻引发的急诊就诊人次的增加趋势明显不同(P 结论:致幻剂引发的急诊就诊人次的增加与大麻引发的急诊就诊人次的增加趋势明显不同):2016 年至 2022 年期间,美国加利福尼亚州致幻剂相关急诊就诊人数和住院人数的相对增幅较大,但绝对增幅较小。
{"title":"Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022","authors":"Nicolas Garel,&nbsp;Steven Tate,&nbsp;Kristin Nash,&nbsp;Anna Lembke","doi":"10.1111/add.16432","DOIUrl":"10.1111/add.16432","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and aims</h3>\u0000 \u0000 <p>Hallucinogens encompass a diverse range of compounds of increasing scientific and public interest. Risks associated with hallucinogen use are under-researched and poorly understood. We aimed to compare the trends in hallucinogen-associated health-care use with alcohol- and cannabis-associated health-care use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, setting and cases</h3>\u0000 \u0000 <p>We conducted an ecological study with publicly available data on International Classification of Diseases, 10th Revision (ICD-10) diagnosis codes associated with emergency department (ED) visits and hospitalizations from the California Department of Healthcare Access and Information (HCAI). HCAI includes primary and secondary ICD-10 codes reported with ED or hospital discharge from every non-federal health-care facility licensed in California, United States, from 2016 to 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Measurements</h3>\u0000 \u0000 <p>ICD-10 codes were classified as hallucinogen-, cannabis- or alcohol-associated if they were from the corresponding category in the ICD-10 block ‘mental and behavioral disorders due to psychoactive substance use’.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Findings</h3>\u0000 \u0000 <p>Observed hallucinogen-associated ED visits increased by 54% between 2016 and 2022, from 2260 visits to 3476 visits, compared with a 20% decrease in alcohol-associated ED visits and a 15% increase in cannabis-associated ED visits. The observed hallucinogen-associated hospitalizations increased by 55% during the same period, from 2556 to 3965 hospitalizations, compared with a 1% increase in alcohol-associated hospitalizations and a 1% increase in cannabis-associated hospitalizations. This rise in hallucinogenic ED visits was significantly different from the trend in cannabis-associated (<i>P</i> &lt; 0.001) and alcohol-associated (<i>P</i> = 0.005) ED visits. The hallucinogen-associated hospitalizations trend also significantly differed when compared with cannabis- (<i>P</i> &lt; 0.001) and alcohol-associated (<i>P</i> &lt; 0.001) hospitalizations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hallucinogen-associated emergency department visits and hospitalizations in California, USA, showed a large relative but small absolute increase between 2016 and 2022.</p>\u0000 </section>\u0000 </div>","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"960-964"},"PeriodicalIF":6.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to apply zero-shot learning to text data in substance use research: An overview and tutorial with media data 如何将零点学习应用于物质使用研究中的文本数据:概述和媒体数据教程。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-11 DOI: 10.1111/add.16427
Benjamin Riordan, Abraham Albert Bonela, Zhen He, Aiden Nibali, Dan Anderson-Luxford, Emmanuel Kuntsche

A vast amount of media-related text data is generated daily in the form of social media posts, news stories or academic articles. These text data provide opportunities for researchers to analyse and understand how substance-related issues are being discussed. The main methods to analyse large text data (content analyses or specifically trained deep-learning models) require substantial manual annotation and resources. A machine-learning approach called ‘zero-shot learning’ may be quicker, more flexible and require fewer resources. Zero-shot learning uses models trained on large, unlabelled (or weakly labelled) data sets to classify previously unseen data into categories on which the model has not been specifically trained. This means that a pre-existing zero-shot learning model can be used to analyse media-related text data without the need for task-specific annotation or model training. This approach may be particularly important for analysing data that is time critical. This article describes the relatively new concept of zero-shot learning and how it can be applied to text data in substance use research, including a brief practical tutorial.

每天都会以社交媒体帖子、新闻报道或学术文章的形式产生大量与媒体相关的文本数据。这些文本数据为研究人员提供了分析和了解如何讨论药物相关问题的机会。分析大型文本数据的主要方法(内容分析或专门训练的深度学习模型)需要大量的人工标注和资源。一种名为 "零点学习 "的机器学习方法可能更快、更灵活,所需的资源也更少。零点学习使用在未标记(或弱标记)的大型数据集上训练的模型,将以前未见过的数据归入模型未专门训练过的类别。这意味着,可以使用已有的零点学习模型来分析与媒体相关的文本数据,而无需进行特定任务标注或模型训练。这种方法对于分析时间紧迫的数据尤为重要。本文介绍了零镜头学习这一相对较新的概念,以及如何将其应用于物质使用研究中的文本数据,包括一个简短的实用教程。
{"title":"How to apply zero-shot learning to text data in substance use research: An overview and tutorial with media data","authors":"Benjamin Riordan,&nbsp;Abraham Albert Bonela,&nbsp;Zhen He,&nbsp;Aiden Nibali,&nbsp;Dan Anderson-Luxford,&nbsp;Emmanuel Kuntsche","doi":"10.1111/add.16427","DOIUrl":"10.1111/add.16427","url":null,"abstract":"<p>A vast amount of media-related text data is generated daily in the form of social media posts, news stories or academic articles. These text data provide opportunities for researchers to analyse and understand how substance-related issues are being discussed. The main methods to analyse large text data (content analyses or specifically trained deep-learning models) require substantial manual annotation and resources. A machine-learning approach called ‘zero-shot learning’ may be quicker, more flexible and require fewer resources. Zero-shot learning uses models trained on large, unlabelled (or weakly labelled) data sets to classify previously unseen data into categories on which the model has not been specifically trained. This means that a pre-existing zero-shot learning model can be used to analyse media-related text data without the need for task-specific annotation or model training. This approach may be particularly important for analysing data that is time critical. This article describes the relatively new concept of zero-shot learning and how it can be applied to text data in substance use research, including a brief practical tutorial.</p>","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"951-959"},"PeriodicalIF":6.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16427","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139424311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder - acknowledging challenges but not giving up on its potential cost-effectiveness 对 Hall 等人的回应:处方精神刺激剂治疗苯丙胺类兴奋剂使用障碍--承认挑战,但不放弃其潜在的成本效益。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-10 DOI: 10.1111/add.16434
Heidar Sharafi, Didier Jutras-Aswad
{"title":"Response to Hall et al.: Prescription psychostimulants for amphetamine-type stimulant use disorder - acknowledging challenges but not giving up on its potential cost-effectiveness","authors":"Heidar Sharafi,&nbsp;Didier Jutras-Aswad","doi":"10.1111/add.16434","DOIUrl":"10.1111/add.16434","url":null,"abstract":"","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 4","pages":"788-789"},"PeriodicalIF":6.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials 减少药物使用作为兴奋剂使用障碍患者的替代有效结果:13 项多地点随机临床试验的结果。
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-10 DOI: 10.1111/add.16409
Masoumeh Amin-Esmaeili, Mehdi Farokhnia, Ryoko Susukida, Lorenzo Leggio, Renee M. Johnson, Rosa M. Crum, Ramin Mojtabai
<div> <section> <h3> Background and aims</h3> <p>Total abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. We aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder.</p> </section> <section> <h3> Design</h3> <p>We conducted a secondary analysis of a pooled dataset of 13 RCTs.</p> </section> <section> <h3> Setting and participants</h3> <p>Participants were individuals seeking treatment for cocaine or methamphetamine use disorders (<i>N</i> = 2062) in a wide range of treatment facilities in the United States.</p> </section> <section> <h3> Measurements</h3> <p>We validated reduced stimulant use against a set of clinical indicators drawn from harmonized measurements, including severity of problems caused by drug use, comorbid depression, global severity of substance use and improvement, severity of drug-seeking behavior, craving and high-risk behaviors, all assessed at the end of the trial, as well as follow-up urine toxicology. A series of mixed effect regression models was conducted to validate reduction in frequency of use against no reduction in use and abstinence.</p> </section> <section> <h3> Findings</h3> <p>More participants reduced frequency of primary drug use than achieved abstinence (18.0% vs. 14.2%, respectively). Reduced use was significantly associated with decreases in craving for the primary drug [60.1%, 95% confidence interval (CI) = 54.3%–64.7%], drug seeking behaviors (41.0%, 95% CI = 36.6%–45.7%), depression severity (39.9%, 95% CI = 30.9%–48.3%), as well as multiple measures of global improvement in psychosocial functioning and severity of drug-related problems, albeit less strongly so than abstinence. Moreover, reduced use was associated with sustained clinical benefit at follow-up, as confirmed by negative urine tests (adjusted odds ratio compared with those with no reduction in use: 0.50, 95% CI = 0.35–0.71).</p> </section> <section> <h3> Conclusion</h3> <p>Reduced frequency of stimulant use appears to be associated with meaningful improvement in various clinical indicators of recovery. Assessment of reduced use, in addition to abstinence, could broaden the scope of outcomes measured in randomized controlled trials of stimulant use disorders and fa
背景和目的:完全禁欲历来是药物使用障碍的治疗目标;然而,在刺激剂使用障碍治疗中,人们越来越认识到减少使用刺激剂作为一种减低伤害的措施所带来的健康益处。我们旨在评估将减少使用兴奋剂作为兴奋剂使用障碍药物干预随机对照试验(RCT)结果衡量标准的有效性:我们对 13 项随机对照试验的汇总数据集进行了二次分析:参与者为在美国各种治疗机构寻求可卡因或甲基苯丙胺使用障碍治疗的人(N = 2062):我们根据一套统一测量方法得出的临床指标验证了兴奋剂使用量的减少,这些指标包括药物使用导致的问题的严重程度、合并抑郁症、药物使用的整体严重程度和改善情况、寻求毒品行为的严重程度、渴求和高危行为,所有指标均在试验结束时进行评估,以及后续尿液毒理学检查。我们采用了一系列混合效应回归模型来验证吸毒频率的减少与吸毒和戒毒的不减少之间的差异:结果:减少主要药物使用频率的参与者多于戒断者(分别为 18.0% 和 14.2%)。减少用药次数与减少对主要毒品的渴求[60.1%,95% 置信区间 (CI) = 54.3%-64.7%]、减少寻求毒品的行为(41.0%,95% CI = 36.6%-45.7%)、减少抑郁的严重程度(39.9%,95% CI = 30.9%-48.3%),以及减少社会心理功能和毒品相关问题严重程度的多种全面改善措施都有明显的关系,尽管这种关系不如禁欲强烈。此外,减少用药与随访时的持续临床获益相关,尿检呈阴性也证实了这一点(与未减少用药者相比,调整后的几率比为 0.50,95% CI):结论:结论:减少兴奋剂的使用频率似乎与各种临床康复指标的显著改善有关。除戒断外,对减少使用的评估可拓宽兴奋剂使用障碍随机对照试验的测量结果范围,并有助于开发更多样化的治疗方法。
{"title":"Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials","authors":"Masoumeh Amin-Esmaeili,&nbsp;Mehdi Farokhnia,&nbsp;Ryoko Susukida,&nbsp;Lorenzo Leggio,&nbsp;Renee M. Johnson,&nbsp;Rosa M. Crum,&nbsp;Ramin Mojtabai","doi":"10.1111/add.16409","DOIUrl":"10.1111/add.16409","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and aims&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Total abstinence has historically been the goal of treatment for substance use disorders; however, there is a growing recognition of the health benefits associated with reduced use as a harm reduction measure in stimulant use disorders treatment. We aimed to assess the validity of reduced stimulant use as an outcome measure in randomized controlled trials (RCTs) of pharmacological interventions for stimulant use disorder.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We conducted a secondary analysis of a pooled dataset of 13 RCTs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting and participants&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Participants were individuals seeking treatment for cocaine or methamphetamine use disorders (&lt;i&gt;N&lt;/i&gt; = 2062) in a wide range of treatment facilities in the United States.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Measurements&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We validated reduced stimulant use against a set of clinical indicators drawn from harmonized measurements, including severity of problems caused by drug use, comorbid depression, global severity of substance use and improvement, severity of drug-seeking behavior, craving and high-risk behaviors, all assessed at the end of the trial, as well as follow-up urine toxicology. A series of mixed effect regression models was conducted to validate reduction in frequency of use against no reduction in use and abstinence.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Findings&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;More participants reduced frequency of primary drug use than achieved abstinence (18.0% vs. 14.2%, respectively). Reduced use was significantly associated with decreases in craving for the primary drug [60.1%, 95% confidence interval (CI) = 54.3%–64.7%], drug seeking behaviors (41.0%, 95% CI = 36.6%–45.7%), depression severity (39.9%, 95% CI = 30.9%–48.3%), as well as multiple measures of global improvement in psychosocial functioning and severity of drug-related problems, albeit less strongly so than abstinence. Moreover, reduced use was associated with sustained clinical benefit at follow-up, as confirmed by negative urine tests (adjusted odds ratio compared with those with no reduction in use: 0.50, 95% CI = 0.35–0.71).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Reduced frequency of stimulant use appears to be associated with meaningful improvement in various clinical indicators of recovery. Assessment of reduced use, in addition to abstinence, could broaden the scope of outcomes measured in randomized controlled trials of stimulant use disorders and fa","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 5","pages":"833-843"},"PeriodicalIF":6.0,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Yes, nitrous oxide addiction undeniably exists! 是的,不可否认,一氧化二氮成瘾是存在的!
IF 6 1区 医学 Q1 PSYCHIATRY Pub Date : 2024-01-09 DOI: 10.1111/add.16430
Caroline Victorri-Vigneau, Marie Grall Bronnec
<p>In their article, Back <i>et al</i>. endeavour to evaluate the ‘symptoms’ of substance use disorder (SUD) associated with nitrous oxide (N2O) use in the literature [<span>1</span>]. While presenting an engaging narrative review, a primary concern arises from the absence of a methodology paragraph, leaving uncertainties regarding their article selection process and eligibility criteria. The authors amalgamate animal studies, recreational clinical cases and pain management situations, blending acute and chronic exposures leading to the non-integration of SUD criteria into a clinical assessment necessitating a specific context (e.g. repeated use in the last year). Extracting each item from its overall clinical context is prone to bias, and does not align with the definition proposed by the American Psychiatric Association (APA) [<span>2</span>]. Interpreting literature data entails the risk of errors and biases, particularly, for example, when evaluating factors such as ‘persistent desire or unsuccessful efforts to cut down or control use of the substance’ using, relapse rates and ‘craving’ through reinforcement studies. Consequently, the authors’ conclusion mirrors their introduction: addiction seems plausible, but substantiating evidence requires more extensive studies.</p><p>However, the reality of N2O addiction is undeniable, and we should have anticipated SUDs. First, there is the history of Horace Wells [<span>3</span>]: as a dentist, he was obsessed with finding a way to alleviate the pain of dental surgery. In 1844, at a public road show exhibition of nitrous oxide, Wells realized its anaesthetic and analgesic potential, witnessing the fall of a man intoxicated with N2O who lacerated his leg to the bone with no pain response. He successfully subjected himself to an extraction of a troublesome third molar under N2O, but continued using it, as well as chloroform, ultimately becoming addicted. As early as 1850, falls and euphoric, analgesic and addictive properties were described. Secondly, there is N2O specific pharmacology; as partially described by Back <i>et al</i>., N2O influences not only the opioid and glutamatergic systems, but also the noradrenergic and GABAergic systems [<span>4</span>], neurotransmissions implicated in addictive mechanisms. All substances that act upon the opioid or GABA system are known to have an addictive potential. Thirdly, there is the evolution of N2O consumption: since 2018, consumption has surged, far surpassing the balloons and ‘five shots’ mentioned by Back <i>et al</i>., reaching levels equivalent to several hundred cartridges daily [<span>5</span>]. N2O has become a public health problem in many countries during the last few years [<span>6</span>].</p><p>While a dedicated clinical study evaluating N2O SUDs may not be possible for ethical reasons, systems exist for this purpose. For instance, France has a health monitoring system coordinated by the French National Agency for the Safety of Medicines and
当出现 N20 使用障碍时,应优先考虑停止消费;无论会出现什么并发症,这都是合乎逻辑的建议,在这种情况下,必须进行成瘾评估,并提出具体的治疗方案。
{"title":"Yes, nitrous oxide addiction undeniably exists!","authors":"Caroline Victorri-Vigneau,&nbsp;Marie Grall Bronnec","doi":"10.1111/add.16430","DOIUrl":"10.1111/add.16430","url":null,"abstract":"&lt;p&gt;In their article, Back &lt;i&gt;et al&lt;/i&gt;. endeavour to evaluate the ‘symptoms’ of substance use disorder (SUD) associated with nitrous oxide (N2O) use in the literature [&lt;span&gt;1&lt;/span&gt;]. While presenting an engaging narrative review, a primary concern arises from the absence of a methodology paragraph, leaving uncertainties regarding their article selection process and eligibility criteria. The authors amalgamate animal studies, recreational clinical cases and pain management situations, blending acute and chronic exposures leading to the non-integration of SUD criteria into a clinical assessment necessitating a specific context (e.g. repeated use in the last year). Extracting each item from its overall clinical context is prone to bias, and does not align with the definition proposed by the American Psychiatric Association (APA) [&lt;span&gt;2&lt;/span&gt;]. Interpreting literature data entails the risk of errors and biases, particularly, for example, when evaluating factors such as ‘persistent desire or unsuccessful efforts to cut down or control use of the substance’ using, relapse rates and ‘craving’ through reinforcement studies. Consequently, the authors’ conclusion mirrors their introduction: addiction seems plausible, but substantiating evidence requires more extensive studies.&lt;/p&gt;&lt;p&gt;However, the reality of N2O addiction is undeniable, and we should have anticipated SUDs. First, there is the history of Horace Wells [&lt;span&gt;3&lt;/span&gt;]: as a dentist, he was obsessed with finding a way to alleviate the pain of dental surgery. In 1844, at a public road show exhibition of nitrous oxide, Wells realized its anaesthetic and analgesic potential, witnessing the fall of a man intoxicated with N2O who lacerated his leg to the bone with no pain response. He successfully subjected himself to an extraction of a troublesome third molar under N2O, but continued using it, as well as chloroform, ultimately becoming addicted. As early as 1850, falls and euphoric, analgesic and addictive properties were described. Secondly, there is N2O specific pharmacology; as partially described by Back &lt;i&gt;et al&lt;/i&gt;., N2O influences not only the opioid and glutamatergic systems, but also the noradrenergic and GABAergic systems [&lt;span&gt;4&lt;/span&gt;], neurotransmissions implicated in addictive mechanisms. All substances that act upon the opioid or GABA system are known to have an addictive potential. Thirdly, there is the evolution of N2O consumption: since 2018, consumption has surged, far surpassing the balloons and ‘five shots’ mentioned by Back &lt;i&gt;et al&lt;/i&gt;., reaching levels equivalent to several hundred cartridges daily [&lt;span&gt;5&lt;/span&gt;]. N2O has become a public health problem in many countries during the last few years [&lt;span&gt;6&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;While a dedicated clinical study evaluating N2O SUDs may not be possible for ethical reasons, systems exist for this purpose. For instance, France has a health monitoring system coordinated by the French National Agency for the Safety of Medicines and ","PeriodicalId":109,"journal":{"name":"Addiction","volume":"119 4","pages":"625-626"},"PeriodicalIF":6.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.16430","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139401044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Addiction
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1